System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Comparative Study Ppublish 4 citations

PubMed: 40662491 DOI: 10.1002/ppul.71059

Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital.

Pediatr Pulmonol 60(7):e71059

Authors: Fuensanta Guerrero-Del-Cueto, Sara Lobato-Lopez, Diego Lozano-Duran, Blanca Sanchez-Duran, Lucia Ramirez-Martin, Begoña Esteban-San-Narciso, Sara Sosa-Hernandez, Laura Martin-Pedraz, David Moreno-Perez, Isabel Leiva-Gea, Esmeralda Nuñez-Cuadros

Affiliations

  • Department of Paediatrics at the Malaga Mother-and-Child Hospital, Hospital Regional Universitario de Malaga, Malaga, Spain.
  • Facultad de Medicina, Universidad de Malaga, Malaga, Spain.
  • Instituto de Investigacion Biomedica de Malaga (Biomedical Research Institute of Malaga), Malaga, Spain.
  • Consejería de Salud y Familias de la Junta de Andalucia, Seville, Spain.

Abstract

INTRODUCTION

This study evaluates nirsevimab's real-world effectiveness in preventing respiratory syncytial virus (RSV) bronchiolitis hospitalizations after its introduction in Andalusia's immunization schedule, compares clinical outcomes between immunized and non-immunized infants (2023-2024), and examines RSV seasonality pre- and post-COVID-19.

METHODS

Retrospective single-center case-control study conducted at a tertiary pediatric hospital (Malaga Regional University Hospital). Infants hospitalized for PCR-confirmed RSV bronchiolitis during the first season after nirsevimab introduction were matched with two controls born on the same day. Immunization status, demographic data, and clinical outcomes were analyzed. As a secondary analysis, clinical characteristics and adverse outcomes of immunized and non-immunized RSV bronchiolitis cases from the 2023-2024 season were compared with four previous periods: pre-pandemic decade (04/2010-03/2020), first pandemic season (04/2020-03/2021), second pandemic season (04/2021-03/2022) and third pandemic season (04/2022-03/2023).

RESULTS

Nirsevimab showed 91.5% effectiveness (95% CI: 71.8%-97.4%) in reducing RSV bronchiolitis hospitalizations, which decreased 72.4% from the pre-pandemic average and 82.4% from 04/2022-03/2023. Intensive-care-unit admissions were significantly higher in non-immunized infants (60.0% vs. 26.1%, p = 0.04), with no differences in bacterial superinfection, oxygen requirement and length-of-stay.

CONCLUSIONS

Nirsevimab significantly reduced RSV bronchiolitis hospitalizations during its first season of use. The study also highlights shifts in RSV seasonality trends influenced by the COVID-19 pandemic, highlighting the need for ongoing surveillance to adapt public health strategies.

MeSH

Respiratory Syncytial Viruses, Epidemiology, Immunization, Hospitalization, Respiratory System, Case-Control Studies, Covid-19, Hospitals, Pediatric, Pandemics, Pediatrics, Bronchiolitis, Infant